Phase IIb trial evaluating the efficacy and tolerability of vaginal telapristone [Proellex-V] in patients with severe menstrual bleeding associated with uterine fibroids

Trial Profile

Phase IIb trial evaluating the efficacy and tolerability of vaginal telapristone [Proellex-V] in patients with severe menstrual bleeding associated with uterine fibroids

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Apr 2016

At a glance

  • Drugs Telapristone (Primary)
  • Indications Uterine leiomyoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Apr 2016 According to a Repros Therapeutics media release, once both - this vaginal and oral (see CTP 242103) studies, complete both 18 week courses of treatment, the company plans to request an end of phase II meeting with the FDA to jointly discuss plans for phase III.
    • 12 Apr 2016 Status changed from recruiting to active, no longer recruiting, according to a Repros Therapeutics media release.
    • 12 Apr 2016 Results published in a Repros Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top